Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

The results of the EVOKE and EVOKE+ trials were comprehensive in showing oral semaglutide’s lack of clinical efficacy for cognition or function in patients with early Alzheimer’s.

A woman is taking legal action after she said a volunteer at senior living center in La Mirada sexually assaulted her mother, who suffers from dementia. KTLA's Kareen Wynter reports on March 20, 2026.

Dementia patients are given antipsychotics, which FDA warns may increase the risk for deat ...

Eli Lilly and Eisai's battle to secure NHS reimbursement for their Alzheimer's disease therapies is dragging on, with guidance blocking use of the drug set for another review. After a successful ...

A woman is taking civil action after alleging that her mother, who has dementia, was sexually assaulted by a senior home ...

A study in the journal Neurology has shown that people with type 1 diabetes are three times more likely to develop dementia ...

In TODAY.com's Expert Tip of The Day, a neurologist explains how playing games that build cognitive speed can protect against ...

Researchers say they have developed a blood test that can help predict the start of Alzheimer's disease symptoms, allowing them to receive a diagnosis.

The NHS will reconsider approving two Alzheimer’s “wonder drugs” after a successful appeal. The National Institute of Health ...

New findings suggest that targeting inflammation in Alzheimer’s may matter as much as targeting protein buildup.

Findings underpin potential of Anavex’ lead candidate blarcamesine through its upstream mechanism of action and SIGMAR1-mediated autophagy restoration ...